Health technology occupies an awkward position in the capital markets. It carries the regulatory burden of healthcare and the adoption risk of enterprise software, and it is therefore underwritten by investors who are fluent in both or by investors who are fluent in neither. Founders who pitch a digital health or device company as a technology story to generalist investors tend to receive generalist valuations — which is to say, discounted ones.

The companies that raise well in this sector lead with the commercial architecture rather than the product. Three questions determine whether an investment committee engages at all.

Question One: Who Actually Pays

The reimbursement pathway is the first thing a sector investor examines and the most common reason a promising product fails to become a business. A clinically excellent tool with no route to payment is a research project with a sales team.

There are four viable payment models in health technology, and each produces a different risk profile:

Companies that can name the payer, the mechanism and the realised amount per unit are in a different conversation from those describing clinical benefit in the abstract.

Question Two: What Clearance Is Required

Regulatory posture determines both the capital requirement and its timing. A clinical decision support tool positioned outside device regulation, a 510(k) device with a cleared predicate, a De Novo submission, and a Class III device requiring full premarket approval represent four materially different capital programmes — differing by years and by an order of magnitude in cost.

Investors do not reward ambiguity here. The strongest position is a clearance strategy specific enough to be criticised: the pathway, the predicate or comparator, the evidence package, the submission timing, and what happens if the agency disagrees. Vagueness about regulatory classification reads to a committee as either inexperience or avoidance, and both carry the same price.

Software companies in particular should be explicit about where the line falls between a regulated device function and an unregulated workflow function, and about what happens to the product if the classification shifts. A company whose entire value proposition sits one reclassification away from a clinical trial requirement is carrying an undisclosed capital need.

The product question is whether it works. The investment question is whether someone who is not the inventor will pay for it a second time.

Question Three: Has Anyone Bought It Twice

Pilots are not revenue. The health technology sector is littered with companies holding impressive logo slides composed entirely of unpaid or heavily discounted pilots that never converted. Sector investors know this and have learned to ask a narrow set of questions:

A company with three renewed contracts and honest unit economics raises more easily, and on better terms, than a company with twenty pilots and a large pipeline.

Structuring the Raise Around the Risk That Remains

Because health technology risk resolves in discrete steps — clearance obtained, code granted, first paid contract, first renewal — the capital is most efficiently raised in tranches tied to those steps rather than as a single round sized to the whole journey.

The dilution difference between these approaches is substantial. Financing an instrument fleet with equity instead of an asset facility, or funding eighteen months of sales build before any contracted revenue exists, are both avoidable. Our comparison of debt and equity funding options works through the trade-offs in detail.

Which Investors to Approach

Investor selection matters more in health technology than in most sectors, because the diligence requires domain knowledge that generalists must either acquire or price around. The relevant pools are specialist healthcare venture and growth funds, strategic corporate investors from device and diagnostics companies, health system venture arms, family offices with healthcare operating experience, and — once there is contracted revenue — venture debt and specialty credit providers.

Each has a different decision process and a different tolerance for regulatory risk. A strategic investor may accept a longer clearance timeline in exchange for commercial rights; a growth fund will not. OAKRG's healthcare capital advisory practice maps the capital requirement against the investors whose mandates actually fit it, and makes curated introductions rather than broad distributions. For companies considering institutional equity more broadly, our guide to preparing for institutional capital covers the readiness work that precedes any process.

The underlying discipline is the same across all of them: name the payer, name the pathway, and show that someone bought it twice.

Frequently Asked Questions

What valuation do digital health companies raise at?

There is no reliable sector-wide figure, and quoted multiples move with the broader market. The more useful observation is what drives the spread: companies with established reimbursement, cleared regulatory status and demonstrated renewals are valued on revenue multiples comparable to enterprise software, while companies carrying unresolved reimbursement or clearance risk are valued far below that, regardless of technology quality. The valuation question is largely settled by how much of the risk has already been retired.

Can a medical device company raise debt before it has revenue?

Generally not conventional debt, because there is no cash flow to service and little collateral. Venture debt typically becomes available once there is institutional equity backing and some contracted revenue. Equipment financing can be available earlier where the company is purchasing or placing identifiable hardware, since the asset itself secures the facility. Before that point, equity and non-dilutive grant funding are the realistic sources.

Are strategic investors better than financial investors for health tech?

They solve different problems. A strategic investor — a device manufacturer, diagnostics company or health system — can supply clinical validation, regulatory experience and distribution that money alone cannot buy, and often tolerates longer timelines. The trade-offs are potential constraints on future exit routes, information rights granted to a possible competitor, and commercial terms that may limit flexibility. Many companies take a minority strategic alongside a financial lead specifically to get the benefit without ceding control of the outcome.

How long does a health technology raise take?

For a company with clean documentation, resolved regulatory classification and demonstrated commercial traction, a growth round commonly runs three to six months from first approach to funding. Companies that begin the process while the data room, reimbursement evidence and clinical validation are still being assembled should assume longer, because diligence in this sector stops whenever a regulatory or payment question cannot be answered immediately.